News

Don’t miss this outstanding review article published by Nature Nanotechnology: ‘A translational framework to DELIVER nanomedicines to the clinic’

Publication: Joyce, P., Allen, C.J., Alonso, M.J. et al. A translational framework to DELIVER nanomedicines to the clinic. Nat. Nanotechnol. (2024). https://doi.org/10.1038/s41565-024-01754-7

Check out our new article: ‘Ionizable nanoemulsions for RNA delivery into the central nervous system – importance of diffusivity’ – OPEN ACCESS

Publication: Mireya L. Borrajo, Aloia Quijano, Philipp Lapuhs, Ana I. Rodriguez-Perez, Shubaash Anthiya, José L. Labandeira-Garcia, Rita Valenzuela, María José Alonso, Ionizable nanoemulsions for RNA delivery into the central nervous system – importance of diffusivity, Journal of Controlled Release, Volume 372, 2024, Pages 295-303, ISSN 0168-3659, https://doi.org/10.1016/j.jconrel.2024.06.051

Check out our new article: ‘Nanotechnology-assisted intracellular delivery of antibody as a precision therapy approach for KRAS-driven tumors’ – OPEN ACCESS

Ana M. López-Estévez, Lucía Sanjurjo, Ángela Turrero, Iker Arriaga, Nicola G.A. Abrescia, Ana Poveda, Jesús Jiménez-Barbero, Anxo Vidal, Dolores Torres, María José Alonso, Nanotechnology-assisted intracellular delivery of antibody as a precision therapy approach for KRAS-driven tumors, Journal of Controlled Release, Volume 373, 2024, Pages 277-292, ISSN 0168-3659, https://doi.org/10.1016/j.jconrel.2024.07.032

Check out our new article: ‘Engineering hyaluronic acid-based nanoassemblies for monoclonal antibody delivery – design, characterization, and biological insights’ – OPEN ACCESS

López-Estévez, A.M., Zhang, Y., Medel, M. et al. Engineering hyaluronic acid-based nanoassemblies for monoclonal antibody delivery – design, characterization, and biological insights. Nano Res. (2024). https://doi.org/10.1007/s12274-024-6826-8

For those of you interested in doing a PhD in Nanomedicine: second call open for the IMDEA Nanociencia Doctoral Training Programme

IDEAL PhD is the IMDEA Nanociencia PhD Programme co-funded by the Horizon Europe Marie Skłodowska-Curie Actions COFUND programme. IDEAL PhD second call will attract 6 pre-doctoral researchers to carry out their thesis projects in one of the research areas developed at the Institute. The second call for IDEAL PhD closes on 23rd August, 2024.

Check out our new article: ‘Nanoemulsions and nanocapsules as carriers for the development of intranasal mRNA vaccines’ – OPEN ACCESS

Borrajo, M.L., Lou, G., Anthiya, S. et al. Nanoemulsions and nanocapsules as carriers for the development of intranasal mRNA vaccines. Drug Deliv. and Transl. Res. (2024). https://doi.org/10.1007/s13346-024-01635-5

Check out our new OPEN ACCESS publication: ‘Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA Consortium’

Marcos-Villar, L., Perdiguero, B., Anthiya, S. et al. Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA Consortium. npj Vaccines 9, 53 (2024). https://doi.org/10.1038/s41541-024-00838-8.

Grand Challenges in Global Health Annual Meeting 2023

Outstanding Grand Challenges Annual Meeting 2023, hosted by the Bill & Melinda Gates Foundation in Dakar

Desarrollo de nanoterapias para la prevención y tratamiento de COVID-19 (NANODCOV)

Expediente: IN852 2021/16 Título: Desarrollo de nanoterapias para la prevención y tratamiento de COVID-19 (NANODCOV) Miembros del Consorcio: Smart Vitamins, Universidad de Santiago de Compostela (USC), Fundación Instituto de Investigación Sanitario de Santiago de Compostela (FIDIS)

María José Alonso’s Lab participates in the NOSEVAC Consortium, a new European collaboration to develop nasal vaccines

María José Alonso’s and Noemi Csaba’s research groups at the Center for Research in Molecular Medicine and Chronic Diseases (CiMUS) of the University of Santiago de Compostela (USC) will participate in the NOSEVAC Consortium, a new European collaboration to develop nasal vaccines.